Loading...
XOSL
NAVA
Market cap41mUSD
Jul 10, Last price  
16.40NOK
1D
-1.80%
1Q
-16.54%
Jan 2017
62.81%
IPO
6.64%
Name

Navamedic ASA

Chart & Performance

D1W1MN
XOSL:NAVA chart
P/E
P/S
0.70
EPS
Div Yield, %
Shrs. gr., 5y
10.65%
Rev. gr., 5y
21.92%
Revenues
565m
+6.38%
386,45131,835,47846,105,18752,593,12155,092,14371,299,22288,683,865151,772,586223,067,740248,348,362274,297,760257,920,665184,021,794188,754,922209,877,000278,439,000382,135,000511,997,000531,436,000565,359,000
Net income
-24m
L
-7,572,040-3,211,794-8,076,59912,815,855-11,187,617-7,159,041-3,254,949-1,268,0001,306,185-10,931,730-10,658,412-15,542,4617,283,775-16,297,223-16,460,000618,00029,432,0003,304,0001,290,000-23,538,000
CFO
26m
-34.99%
-10,740,7465,557,727-10,660,689-1,646,961-13,463,669-95,521-6,473,430-15,650,876-10,748,49922,628,650-14,508,25159,073,633-36,023,97812,722,136-3,180,000-1,300,00017,941,0002,179,00039,354,00025,585,000
Dividend
Apr 13, 20101 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
IPO date
Mar 31, 2006
Employees
45
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT